EMA granted clearance to advance belrestotug 400mg + dostarlimab as recommended Phase 3 dose and activate GALAXIES Lung-301 clinical sites in the EU- Interim data from inupadenant Phase 2 A2A-005 in ...

Domvanalimab (dom). The company’s most advanced asset is dom, an Fc-silent anti-TIGIT monoclonal antibody that is undergoing evaluation in three registrational trials for the treatment of ...

TIGIT drugs from Merck & Co, Bristol-Myers Squibb/Agenus, Gilead/Arcus, GlaxoSmithKline/iTeos Therapeutics and Mereo Biopharma are in clinical trials already. It remains to be seen if tiragolumab ...

This page features the latest news about the Iteos stock. Iteos Therapeutics stock hits 52-week low at $8.49 Iteos Therapeutics Inc. (NASDAQ: ITOS) stock has reached a 52-week low, touching down ...

Featured here, the Income Statement (earnings report) for Iteos Therapeutics Inc, showing the company's financial performance from operating and non operating activities such as revenue ...

You'll find Call and Put Strike Prices, Last Price, Change, Volume, Implied Volatility, Theoretical and Greeks for Iteos options for the expiration dates selected. Below this information you can also ...